Enwave Corporation · TSXV:ENW
Enwave — Shareholder Meeting (2010)
10 slides from Enwave's shareholder meeting presentation, Nov 28, 2010
Slide 1: Revolutionary Dehydration Technology
Revolutionary Dehydration Technology AGM 2010 Presentation
Slide 2: Corporate Mission
Corporate Mission AGM 2010 EnWave’s mission continues to be focused on replacing freeze drying technologies globally. Towards accomplishing this mission, the company made a number of major steps forward in 2009, and is focused on 5 key targets for 2010.
Slide 3: REV Market Opportunity
REV Market Opportunity Globally diversified market opportunity (USD$Bn) $4 Estimated 2008 global Vaccines & therapeutic market for REV $25 $31 antibodies Antibiotics & other technology applications pharmaceuticals = USD$133Bn Non-regulated biologics (Reagents) Powdered drinks & coffee $10 Probiotics
Slide 4: 2009 Accomplishments
2009 Accomplishments nutraREV™ powderREV™ bioREV™ & freezeREV™ www.enwave.net | TSX-V: ENW | FSE: E4U
Slide 5: nutraREV Division
nutraREV™ Division Commercial-scale food and ingredient dehydration Sale of first commercial nutraREV™ machine for blueberries IFT 2009 Innovation Award LOI with IFS/Smartpac for banana chips in Central America Over 20 CA’s with global food processing companies Bioseutica’s successful encapsulated l
Slide 6: powderREV Division
powderREV™ Division Processing biological materials in bulk Completed successful testing comparison versus freeze dried for Danisco probiotic bacteria using vial technology Designed and built a gram-quantity prototype for Danisco showing proof-of-concept could save up to 80% in processing costs Desi
Slide 7: bioREV/freezeREV
bioREV™/freezeREV™ High-speed pharmaceutical dehydration Signed testing agreement with Saskatchewan Research Council Showed promising results on antibodies and enzymes Began discussions with pharmaceutical companies Designed multi-vial prototype options Biomaterials and vaccine patents received posi
Slide 8: 2009 Corporate Achievements
2009 Corporate Achievements Market cap increased from CDN$10M to CDN$60M Share liquidity improvement of nearly 300%, target was 255 Raised over $6.0M in equity and government grants Increased I.R. Activities in Canada & Europe with SectorSpeak and BankM Established broker relationships with Canaccor
Slide 9: 2010 Key Targets
2010 5 Key Targets “Increasing Momentum” Build & test continuous pilot version of powderREV™ and negotiate license agreement with Danisco by early next year Establish pilot faiclity and sell at least two nutraREV™ machines Close two new multi-national technology testing collaborations Develop bioREV
Slide 10: Contact Details
Contact Details John McNicol Jennifer Thompson President & Co-CEO V.P. Corporate Development & Investor Relations Phone: (604) 601-8524 Cell: (604) 603-2959 Cell: (604) 603-6549 Email: john.mcnicol@enwave.net Email: jthompson@enwave.net www.enwave.net | TSX-V: ENW | FSE: E4U